ENDRA Life Sciences Activates TAEUS System To Initiate Clinical Study At LMU University Hospital In Germany; Scans First Patient In Post-CE Mark Clinical Study With Munich's Center Of Excellence In Europe's Largest Healthcare Market
Portfolio Pulse from Benzinga Newsdesk
ENDRA Life Sciences has initiated a clinical study at LMU University Hospital in Germany, scanning the first patient with its TAEUS liver system. The study aims to assess TAEUS' liver fat measurement capabilities against the MRI-PDFF test, providing real-world evidence for metabolic disease management.
October 22, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ENDRA Life Sciences has started a clinical study in Germany using its TAEUS system, marking a significant step in validating its liver fat measurement capabilities against MRI-PDFF. This could enhance the system's credibility and adoption in metabolic disease management.
The initiation of a clinical study in a leading European medical center enhances the credibility of ENDRA's TAEUS system. Successful validation against the MRI-PDFF test could lead to increased adoption and market penetration, positively impacting NDRA's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90